Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 40 recruiting now official registry

Migraine clinical trials

40 of 105 indexed Migraine trials are currently recruiting.

105 US clinical trials · 40 currently recruiting

Migraine is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 40 of them currently open to new participants. 33 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 7 of these trials.

The research picture

Migraine has 105 registered US clinical trials, 40 of them open to new participants right now, about 38% of the total.

40
recruiting participants now
38%
of trials open to enrollment
33
in Phase 3–4 (later-stage)
7
top sponsor: Pfizer
Phase 18Phase 212Phase 320Phase 413

Active & Recent Trials

105 total, page 2 of 3

ACTIVE NOT RECRUITING NA 50 participants

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

HonorHealth Research Institute

NCT05175521

ACTIVE NOT RECRUITING NA 30 participants

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: A Single Arm Study

Maharishi International University

NCT06695156

ACTIVE NOT RECRUITING NA 30 participants

Migraine and CVD Risk in Women

University of Pennsylvania

NCT03081390

ACTIVE NOT RECRUITING 1 participants

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Pfizer

NCT05198245

COMPLETED Phase 3 1,978 participants

Randomized Trial in Adult Participants With Acute Migraines

Pfizer

NCT04571060

COMPLETED 1,944 participants

Family Study of Affective and Anxiety Spectrum Disorders

National Institute of Mental Health (NIMH)

NCT00071786

COMPLETED Phase 3 1,633 participants

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Eli Lilly and Company

NCT03670810

COMPLETED Phase 2 1,590 participants

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

Pfizer

NCT03732638

COMPLETED NA 607 participants

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

Cefaly Technology

NCT03465904

COMPLETED Phase 4 580 participants

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Eli Lilly and Company

NCT05127486

COMPLETED NA 568 participants

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Click Therapeutics

NCT05853900

COMPLETED Phase 2 526 participants

Prevention Study in Adult Patients Suffering From Migraine Headaches

XenoPort

NCT00742209

COMPLETED Phase 4 512 participants

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Amgen

NCT04252742

COMPLETED Phase 3 506 participants

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Teva Branded Pharmaceutical Products R&D

NCT04530110

COMPLETED 391 participants

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

AbbVie

NCT05653986

COMPLETED Phase 2 313 participants

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

AOBiome

NCT03488563

COMPLETED Phase 3 300 participants

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

Abbott

NCT00195741

COMPLETED 292 participants

Identifying Factors Underlying the Discontinuation of Triptans

Mayo Clinic

NCT00890357

COMPLETED Phase 3 235 participants

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Teva Branded Pharmaceutical Products R&D

NCT04458857

COMPLETED Phase 3 200 participants

A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

Diamond Headache Clinic

NCT00300924

COMPLETED Phase 4 197 participants

Two Rizatriptan Prescribing Portions for Treatment of Migraine

Clinvest

NCT00397254

COMPLETED NA 179 participants

Treatment for Migraines With an Implantable Device

Boston Scientific Corporation

NCT00286078

COMPLETED Phase 3 173 participants

Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine

Texas Cardiac Arrhythmia Research Foundation

NCT01391091

COMPLETED 162 participants

Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

Novartis Pharmaceuticals

NCT05375097

COMPLETED Phase 3 157 participants

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

Wake Forest University Health Sciences

NCT05967442

COMPLETED Phase 4 127 participants

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Montefiore Medical Center

NCT02389829

COMPLETED Phase 3 110 participants

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Click Therapeutics

NCT06004388

COMPLETED Phase 2 104 participants

Treximet Early Intervention Adolescent Migraine

Premiere Research Institute

NCT01016678

COMPLETED Phase 3 100 participants

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

Axsome Therapeutics

NCT05550207

COMPLETED 97 participants

A Complex Contraception Registry

University of California, San Diego

NCT02219269

COMPLETED Phase 2 92 participants

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

University of California, San Diego

NCT04360044

COMPLETED Phase 2 84 participants

CHOCOlate MeLatonin for AdolescenT MigrainE

Amy Gelfand

NCT03597529

COMPLETED Phase 2 78 participants

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Manistee Therapeutics

NCT06728553

COMPLETED NA 75 participants

ACT for High Frequency Migraine; A Virtual Mindfulness Intervention

Brigham and Women's Hospital

NCT05003362

COMPLETED Phase 3 73 participants

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

Pfizer

NCT00510419

COMPLETED Phase 4 65 participants

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Eli Lilly and Company

NCT04294147

COMPLETED NA 61 participants

Integrative Migraine Pain Alleviation Through Chiropractic Therapy

Harvard University Faculty of Medicine

NCT03177616

COMPLETED Phase 4 60 participants

Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache

Western University of Health Sciences

NCT01332864

COMPLETED Phase 1 60 participants

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Acorda Therapeutics

NCT02905227

COMPLETED NA 59 participants

Abortive Treatment of Migraine With the Cefaly® Abortive Program Device

Cefaly Technology

NCT03217968

COMPLETED Phase 1 52 participants

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

H. Lundbeck A/S

NCT05304910

COMPLETED Phase 1 46 participants

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Satsuma Pharmaceuticals

NCT03874832

COMPLETED Phase 1 42 participants

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Eli Lilly and Company

NCT03076970

COMPLETED Phase 1 40 participants

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Allergan

NCT04179474

COMPLETED Phase 3 34 participants

Metformin for the Prevention of Episodic Migraine (MPEM)

Mayo Clinic

NCT02593097

COMPLETED NA 33 participants

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions

Roxane Laboratories

NCT01161654

COMPLETED NA 32 participants

STOPAIN in the Treatment of a Single Migraine Attack

Thomas Jefferson University

NCT01687101

COMPLETED NA 30 participants

Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine

ElectroCore

NCT01532830

COMPLETED Phase 3 28 participants

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

Montefiore Medical Center

NCT02665273

COMPLETED NA 26 participants

An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine

Mike O'Callaghan Military Hospital

NCT02764996

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 12
Phase 3 20
Phase 4 13

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Migraine Trial Landscape

105 indexed Migraine studies · 40 recruiting (38%).

Phase mix: 33 late (III/IV) vs 20 early (I/II).

Top sponsor: Pfizer (7 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Migraine?

PlainTrial tracks 105 US clinical trials for Migraine, of which 40 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Migraine?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.